Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSMB8 | P28062 | 2/20 | 0.33 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18785827 | 0.90 | KMT2A (0.34) | PSMB8PSMB5LMNAKMT2ASMN1; SMN2 | |
| SCHEMBL14207255 | 0.87 | SMN1; SMN2 (0.38) | PSMB8PSMB5KMT2ASMN1; SMN2 | |
| SCHEMBL21182266 | 0.87 | SMN1; SMN2 (0.38) | PSMB8PSMB5KMT2ASMN1; SMN2 | |
| SCHEMBL1728021 | 0.86 | PSMB8 (0.32) | PSMB8PSMB5LMNA | |
| SCHEMBL9285468 | 0.85 | ALDH1A1 (0.34) | PSMB8PSMB5LMNAKMT2ASMN1; SMN2 | |
| SCHEMBL43720 | 0.85 | TSHR (0.34) | PSMB8PSMB5LMNA | |
| SCHEMBL13907086 | 0.84 | PSMB8 (0.30) | PSMB8PSMB5 | |
| SCHEMBL19027389 | 0.83 | TSHR (0.35) | PSMB8PSMB5LMNAKMT2ASMN1; SMN2 | |
| SCHEMBL264659 | 0.83 | CYP2C19 (0.32) | PSMB8PSMB5LMNA | |
| SCHEMBL43576 | 0.82 | PSMB8 (0.35) | PSMB8PSMB5LMNAKMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2014171899-A1 | TUNABLE FLUORESCENCE USING CLEAVABLE LINKERS | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2014-10-23 | — | — | WO | disclosed |
| US-8546493-B2 | Multi-armed, monofunctional, and hydrolytically stable derivatives of poly(ethylene glycol) and related polymers for modification of surfaces and molecules | NEKTAR THERAPEUTICS (US) | 2013-10-01 | — | — | US | disclosed |
| US-20130177961-A1 | MULTI-ARMED, MONOFUNCTIONAL, AND HYDROLYTICALLY STABLE DERIVATIVES OF POLY(ETHYLENE GLYCOL) AND RELATED POLYMERS FOR MODIFICATION OF SURFACES AND MOLECULES | NEKTAR THERAPEUTICS (US) | 2013-07-11 | — | — | US | disclosed |
| US-20110130550-A1 | PROTEIN MONOMER, PROTEIN POLYMER OBTAINED FROM SAID MONOMER, AND DEVICE THAT CONTAINS THEM | OSAKA UNIVERSITY (JP) | 2011-06-02 | — | — | US | disclosed |
| US-20100249375-A1 | IMMOBILIZING MOLECULES ON A SOLID SUPPORT | TACNIA PTY LTD (AU) | 2010-09-30 | — | — | US | disclosed |
| WO-2008141799-A1 | OLIGOPHOSPHORAMIDATES | ROCHE DIAGNOSTICS GMBH (DE) | 2008-11-27 | — | — | WO | disclosed |
| US-7419600-B2 | Method for purifying a branched water-soluble polymer | NEKTAR THERAPEUTICS AL, CORPORATION (US) | 2008-09-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110130550-A1 | PROTEIN MONOMER, PROTEIN POLYMER OBTAINED FROM SAID MONOMER, AND DEVICE THAT CONTAINS THEM | MAX, MLX, MRPL21 | PSMB8 931/4885PSMB5 1151/4885LMNA 3032/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.